Karolinska Developments portföljbolag SVF Vaccines inleder klinisk fas 1-studie med universellt vaccin mot covid-19
February 28, 2023 11:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 28 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines, tidigare Svenska Vaccinfabriken Produktion AB, har inlett en...
Karolinska Development’s portfolio company Aprea Therapeutics secures funding of USD 5.5 million
February 28, 2023 11:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has closed an underwritten public offering of USD 5.5...
Karolinska Developments portföljbolag Modus Therapeutics presenterar positiva resultat från en klinisk studie med sevuparin
February 21, 2023 11:25 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 21 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics presenterat positiva resultat från bolagets kliniska fas...
Karolinska Development’s portfolio company Modus Therapeutics presents positive results from a clinical trial of sevuparin
February 21, 2023 11:25 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN February 21, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has presented positive results from the company’s...
Bokslutskommuniké för januari – December 2022
February 17, 2023 02:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM – den 17 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin bokslutskommuniké för januari - december 2022. Den fulla rapporten är tillgänglig på bolagets...
Year-end Report - January-December 2022
February 17, 2023 02:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM – 17 February 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report - January-December 2022. The full report is available on the Company's website. ...
Karolinska Developments portföljbolag Dilafor redovisar bibehållen effekt från förlängningsstudie med tafoxiparin
February 14, 2023 13:15 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 14 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Dilafors förlängda kliniska fas 2b-studie med läkemedelskandidaten tafoxiparin...
Karolinska Development’s portfolio company Dilafor reports maintained effect in the extension study of tafoxiparin
February 14, 2023 13:15 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – February 14, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate...
Karolinska Developments portföljbolag Umecrine Cognition beviljas Orphan Drug Designation av FDA för golexanolon
January 17, 2023 02:45 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 17 januari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har beviljats orphan drug designation av den amerikanska...
Karolinska Development’s portfolio company Umecrine Cognition is granted Orphan Drug Designation by the FDA for golexanolone
January 17, 2023 02:45 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – January 17, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been granted Orphan Drug Designation by the...